Quick Dispatch:
Your tirzepatide surpass-5 Results of SURPASS-1-5 for tirzepatide treatment in T2D orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your tirzepatide surpass-5 Results of SURPASS-1-5 for tirzepatide treatment in T2D ships.
Need Help?
Questions about tirzepatide surpass-5 Results of SURPASS-1-5 for tirzepatide treatment in T2D, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for tirzepatide surpass-5 Results of SURPASS-1-5 for tirzepatide treatment in T2D in your area.
Dual GIP/GLP-1 receptor agonist as an innovative therapeutic option
23.09
SURMOUNT-5: Tirzepatide and semaglutide go head-to-head in battle of weight loss drugs
23.10
SURPASS-5 Data: Tirzepatide Plus Insulin Glargine Improve Glycemic Control in T2D
26.51
SURPASS-CVOT Shows Mounjaro Surpasses Trulicity in CV Outcomes
22.24
Time spent in glycaemic control with sustained body weight reduction with tirzepatide: A post hoc analysis of the SURPASS clinical trial programme - Bergman - 2025 - Diabetes, Obesity and Metabolism
20.69
Tirzepatide Improved Health-Related Quality of Life Compared with Insulin Lispro in Basal Insulin-Treated Adults with Type 2 Diabetes and Inadequate Glycaemic Control: A Randomised Controlled Phase 3b Trial (SURPASS-6)
29.92
01324-6/asset/f8796f89-5117-40f3-b350-bca267093e71/main.assets/gr1.gif)
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
27.90
